Assessment of Treatment Response to Dc Vaccine in Recurrent GBM Patients Using Multiparametric Mri Prediction Model

Abstract

The highly aggressive nature of glioblastoma (GBM) leads to a dismal prognosis, and alternative therapies are being sought. Immunotherapy, such as the Dendritic Cell (DC) vaccine, is currently being evaluated for recurrent GBMs in clinical trials. Follow-up imaging after this immunotherapeutic approach often mimics disease progression on conventional images, making standard MRI evaluation challenging. Our findings indicate that our previously established multiparametric MRI-based prediction model has the capacity to accurately assess response to DC vaccine in recurrent GBM patients, objectively characterizing as either TP or PsP GBM patients, avoiding interruptions in satisfactory treatments, and preventing invasive procedures in PsP cases.